Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan [Corrigendum]
Hisanaga K, Uchino H, Kakisu N, et al. Diabetes Metab Syndr Obes. 2021;14:773—781. Page 775, left column, third paragraph, line 4, the text “(p<0.5)” should read “(p<0.05)”. Page 775, left column, second line from the bottom, the text &...
Guardado en:
Autores principales: | Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2d95d3f51214e5e8c9da4e051790227 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
por: Hisanaga K, et al.
Publicado: (2021) -
Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021) -
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021) -
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
por: A. I. Chertkova, et al.
Publicado: (2018) -
Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Guang‐Li Zhu, et al.
Publicado: (2021)